相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG MS study
Tanuja Chitnis et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
Rosa C. Lucchetta et al.
CNS DRUGS (2018)
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Andrea Huwiler et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Tanuja Chitnis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Burhan Z. Chaudhry et al.
NEUROTHERAPEUTICS (2017)
Multiple sclerosis, a treatable disease
Anisha Doshi et al.
CLINICAL MEDICINE (2017)
The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases
Yang Mao-Draayer et al.
CLINICAL IMMUNOLOGY (2017)
From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?
Frederic J. Zecri
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study
Ludwig Kappos et al.
JAMA NEUROLOGY (2016)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis
Loredana La Mantia et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Interferons-beta versus glatiramer acetate for relapsingremitting multiple sclerosis
Loredana La Mantia et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Gray matter atrophy in multiple sclerosis: A longitudinal study
Elizabeth Fisher et al.
ANNALS OF NEUROLOGY (2008)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
T Kuhlmann et al.
BRAIN (2002)
分享论文
